The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1267-1282

  Tamamura, Hirokazu ^a,b   Fujii, Nobutaka ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cancer cell progression; Cancer metastasis; Chemokine receptor; HIV infection; Low molecular weight CXCR4 antagonist; Rheumatoid arthritis (RA); T140; T22

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ALPHA N ACETYLNONA DEXTRO ARGININE AMIDE; AMD 070; AMD 3465; AMD 3645; AMD 8665; CHEMOKINE RECEPTOR AFFECTING AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; DEXAMETHASONE; ENFUVIRTIDE; FC 131; FC 151; FC 341; FC 351; FLUDARABINE; KRH 1636; N (6 AMINOHEXYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N (3 GUANIDINOPROPYL)GLYCYL N BENZYLGLYCYL N (3 GUANIDINOPROPYL)GLYCYL DEXTRO LYSYL DEXTRO LYSYL DEXTRO ARGINYL DEXTRO PROLINAMIDE; POLYLACTIC ACID; POLYPEPTIDE; POLYPHEMUSIN 2; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STROMAL CELL DERIVED FACTOR 1; T 140; T 140 DERIVATIVE; T 22; TACHYPLESIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; B LYMPHOCYTE; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CELL TYPE; CHRONIC LYMPHATIC LEUKEMIA; COST OF ILLNESS; DELAYED HYPERSENSITIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; LEUKEMIA CELL; LUNG METASTASIS; LUNG SMALL CELL CANCER; MELANOMA CELL; METASTASIS; MICROCAPSULE; MOUSE; NONHUMAN; OSMOTIC PUMP; PANCREAS CANCER; PRE B LYMPHOCYTE; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SHEEP ERYTHROCYTE; SIDE EFFECT; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; CELL MIGRATION INHIBITION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; RECEPTORS, CXCR4;

EID: 28944452573     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1267     Document Type: Review

References (92)

1. NAGASAWA T, KIKUTANI H, KISHIMOTO T: Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc. Natl. Acad. Sci. USA (1994) 91:2305-2309.
2. BLEUL CC, FARZAN M, CHOE H et al.: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 382:829-833.
3. OBERLIN E, AMARA A, BACHELERIE F et al.: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 382:833-835.
4. TASHIRO K, TADA H, HEILKER R, SHIROZU M, NAKANO T, HONJO T: Signal sequence trap: a cloning strategy for secreted proteins and Type I membrane proteins. Science (1993) 261:600-603.
5. FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry co-factor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872-877.
6. MÜLLER A, HOMEY B, SOTO H et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 410:50-56.
7. KOSHIBA T, HOSOTANI R, MIYAMOTO Y et al.: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. (2000) 6:3530-3535.
8. MORI T, DOI R, KOIZUMI K et al.: CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol. Cancer Ther. (2004) 3:29-37.
9. ROBLEDO MM, BARTOLOME RA, LONGO N et al.: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J. Biol. Chem. (2001) 276:45098-45105.
10. TAKENAGA M, TAMAMURA H, HIRAMATSU K et al.: A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem. Biophys. Res. Commun. (2004) 320:226-231
11. TAICHMAN RS, COOPER C, KELLER ET, PIENTA KJ, TAICHMAN NS, MCCAULEY LK: Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer matastasis to bone. Cancer Res. (2002) 62:1832-1837.
12. SCHRADER AJ, LECHNER O, TEMPLIN M et al.: CXCR4/CXCL12 expression and signaling in kidney cancer. Br. J. Cancer (2002) 86:1250-1256.
13. GEMINDER H, SAGI-ASSIF O, GOLDBERG L et al.: A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. (2001) 167: 4747-4757.
14. BERTOLINI F, DELL'AGNOLA C, MANCUSO P et al.: CXCR4 neutralization, a novel therapeutic approach for non-Hodgkids lymphoma. Cancer Res. (2002) 62:3106-3112.
15. KIJIMA T, MAULIK G, MA PC et al.: Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. (2002) 62:6304-6311.
16. BURGER M, GLODEK A, HARTMANN T et al.: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene (2003) 22:8093-8101.
17. SCOTTON CJ, WILSON JL, MILLIKEN D, STAMP G, BALKWILL FR: Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. (2001) 61:4961-4965.
18. SCOTTON CJ, WILSON JL, SCOTT K et al.: Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. (2002) 62:5930-5938.
19. SANZ-RODRIGUEZ F, HIDALGO A, TEIXIDO J: Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood (2001) 97:346-351.
20. ZANNETTINO ACW, FARRUGIA AN, KORTESIDIS A et al.: Elevated serum levels of SDF-1α are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients Cancer Res. (2005) 65:1700-1709.
21. TSUKADA N, BURGER JA, ZVAIFLER NJ, KIPPS TJ et al.: Distinctive features of 'nurselike' cells that differentiate in the context of chronic lymphocytic leukemia. Blood (2002) 99:1030-1037.
22. BURGER M, HARTMANN T, KROME M et al.: Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood (2005) 106:1824-1830.
23. JUAREZ J, BRADSTOCK KF, GOTTLIEB DJ, BENDALL LJ: Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia (2003) 17:1294-1300.
24. RUBIN JB, KUNG AL, KLEIN RS et al.: A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. USA (2003) 100:13513-13518.
25. TAMAMURA H, HORI A, KANZAKI N et al.: T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. (2003) 550:79-83.
26. PIOVAN E, TOSELLO V, INDRACCOLO S et al.: Chemokine receptor expression in EBV-associated lymphoproliferation in Hu/SCID mice: Implications for CXCL12/CXCR4 axis in lymphoma generation. Blood (2005) 105:931-939.
27. NANKI T, HAYASHIDA K, EL-GABALAWY HS et al.: Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J. Immunol. (2000) 165:6590-6598.
28. DENG H, LIU R, ELLMEIER W et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661-666.
29. DRAGIC T, LITWIN V, ALLAWAY GP et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 381:667-673.
30. ALKHATIB G, COMBADIERE C, BRODER CC et al.: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 272:1955-1958.
31. CHOE H, FARZAN M, SUN Y et al.: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 85:1135-1148.
32. DORANZ BJ, RUCKER J, YI Y et al.: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 85:1149-1158.
33. BALKWILL F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. (2004) 14:171-179.
34. CHAN DC, KIM PS: HIV entry and its inhibition. Cell(1998) 93:681-684.
35. MITSUYA H, ERICKSON J: Drug development. A. Discovery and development of antiretroviral therapeutics for HIV infection. In: Textbook of AIDS Medicine. Merigan TC, Bartlett JG, Bolognesi D (Eds), Williams & Wilkins, Baltimore (1999):751-780.
36. BARBARO G, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. (2005) 11:1805-1843.
37. TAMAMURA H, OTAKA A, FUJII N: Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/ CCR5 antagonists and gp41-C34-remodeling peptides. Curr. HIV Res. In press.
38. NAKAMURA T, FURUNAKA H, MIYATA T et al.: Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). J. Biol. Chem. (1988) 263:16709-16713.
39. MIYATA T, TOKUNAGA F, YONEYA T et al.: Antimicrobial peptides, isolated from horseshoe crab hemocytes, tachyplesin II, and polyphemusins I and II: chemical structures and biological activity J. Biochem. (1989) 106:663-668.
40. MASUDA M, NAKASHIMA H, UEDA T et al.: A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin II). Biochem. Biophys. Res. Commun. (1992) 189:845-850.
41. NAKASHIMA H, MASUDA M, MURAKAMI T et al.: Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7] polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother. (1992) 36:1249-1255.
42. TAMAMURA H, XU Y, HATTORI T et al.: A low molecular weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem. Biophys. Res. Commun. (1998) 253:877-882.
43. MURAKAMI T, NAKAJIMA T, KOYANAGI Y et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. (1997) 186:1389-1393.
44. XU Y, TAMAMURA H, ARAKAKI R et al.: Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res. Hum. Retroviruses (1999) 15:419-427.
45. MURAKAMI T, ZHANG T.-Y., KOYANAGI Y et al.: Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus Type 1 infection. J. Virol. (1999) 73:7489-7496.
46. TAMAMURA H, SUGIOKA M, ODAGAKI Y et al.: Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity. Bioorg. Med. Chem. Lett. (2001) 11:359-362 and 2409.
47. TAMAMURA H, OMAGARI A, OISHI S et al.: Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg. Med. Chem. Lett. (2000) 10:2633-2637.
48. TAMAMURA H, OMAGARI A, HIRAMATSU K et al.: Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett. (2001) 11:1897-1902.
49. TAMAMURA H, HIRAMATSU K, KUSANO S et al.: Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org. Biomol. Chem. (2003) 1:3656-3662.
50. TAMAMURA H, HIRAMATSU K, MIZUMOTO M et al.: Enhancement of the T140-based pharmacophores leads to the development of more potent and biostable CXCR4 antagonists. Org. Biomol. Chem. (2003) 1:3663-3669.
51. WILD CT, SHUGARS DC, GREENWELL TK et al.: Peptides corresponding to a predictive alpha-helical domain of human-immunodeficiency-virus type-1 gp41 are potent inhibitors of virus-infection. Proc. Natl. Acad. Sci. USA. (1994) 91:9770-9774.
52. KANBARA K, SATO S, TANUMA J et al.: Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res. Hum. Retroviruses (2001) 17:615-622.
53. MURAKAMI T, MAKI W, CARDONES AR et al.: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. (2002) 62:7328-7334.
54. IHDE D, PASS H, GLASTEIN: Small cell lung cancer. In: Cancer. Principles and Practice of Oncology. 4th Edn. VTJ De Vita, S Hellmann, SA Rosenberg (Eds), JB Lippincott: Philadelphia (1993):591-687.
55. HARTMANN TN, BURGER JA, GLODEK A, FUJII N, BURGER M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene (2005) 24:4462-4471.
56. TAMAMURA H, FUJISAWA M, HIRAMATSU K et al.: Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett. (2004) 569:99-104.
57. ZHANG W, NAVENOT JM, HARIBABU B et al.: A point mutation that confers constitutive activity to CXCR4 reveals T140 is an inverse agonist and AMD3100 and ALX40-4C are weak partial agonists. J. Biol. Chem. (2002) 277:24515-24521.
58. TRENT JO, WANG Z, MURRAY JL et al.: Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J. Biol. Chem. (2003) 278:47136-47144.
59. PENG H, HUANG Y, ROSE J et al.: Stromal cell-derived factor 1-mediated CXCR4 signaling in fat and human cortical neural progenitor cells. J. Neurosci. Res. (2004) 76:35-50.
60. ALLEN CDC, ANSEL KM, LOW C et al.: Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. (2004) 5:943-952.
61. FUKAMI T, NAGASE T, FUJITA K et al.: Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J. Med. Chem. (1995) 38:4309-4324.
62. 3 antagonists. J. Am. Chem. Soc. (1996) 118:7461-7472.
63. SPATOLA AF, CROZET Y, DEWIT D, YANAGISAWA M. Rediscovering an endothelin antagonist (BQ-123): A self-deconvoluting cyclic pentapeptide library. J. Med. Chem. (1996) 39:3842-3846.
64. 3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J. Am. Chem. Soc. (1997) 119:1328-1335.
65. PORCELLI M, CASU M, LAI A et al.: Cyclic pentapeptides of chiral sequence DLDDL as scaffold for antagonism of G-protein coupled receptors: synthesis, activity and conformational analysis by NMR and molecular dynamics of ITF 1565 a substance P inhibitor. Biopolymers (1999) 50:211-219.
66. NIKIFOROVICH GV, KOVER KE, ZHANG W-J, MARSHALL GR: Cyclopentapeptides as flexible conformational templates. J. Am. Chem. Soc. (2000) 122:3262-3273.
67. FUJII N, OISHI S, HIRAMATSU K et al.: Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation-and sequence-based libraries. Angew. Chem. Int. Ed. Engl. (2003) 42:3251-3253.
68. 2 sites. J. Med. Chem. (1990) 33:838-845.
69. WIPF P, FRITCH PC: SN2' reactions of peptide aziridines. A cuprate-based approach to (E)-alkene isosteres. J. Org. Chem. (1994) 59:4875-4886.
70. N2' ring opening of aziridines bearing an α,β-unsaturated ester group with organocopper reagents. A new stereoselective synthetic route to (E)-alkene dipeptide isosteres. J. Chem. Soc. (1995):1359-1371.
71. DALY MJ, WARD RA, THOMPSON DF, PROCTER G.: Allylsilanes in organic synthesis; stereoselective synthesis of transalkene peptide isosteres. Tetrahedron Lett. (1995) 36:7545-7548.
72. TAMAMURA H, HIRAMATSU K, MIYAMOTO K et al.: Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the βII'-turn moiety. Bioorg. Med. Chem. Lett. (2002) 12:923-928.
73. TAMAMURA H, KOH Y, UEDA S et al.: Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multi-drug resistant HIV-1 strains. J. Med. Chem. (2003) 46:1764-1768.
74. TAMAMURA H, YAMASHITA M, MURAMATSU H et al.: Regiospecific ring-opening reactions of aziridines bearing an αβ-unsaturated ester group with trifluoroacetic acid or methanesulfonic acid: Application to the stereoselective synthesis of (E)-alkene dipeptide isosteres. Chem. Commun. (1997) 2327-2328.
75. TAMAMURA H, YAMASHITA M, NAKAJIMA Y et al.: Regiospecific ring-opening reactions of β-aziridinyl α,β-enoates with acids: application to the stereoselective synthesis of a couple of diastereoisomeric (E)-alkene dipeptide isosteres from a single β-aziridinyl α,β-enoate and to the convenient preparation of amino alcohols bearing α,β-unsaturated ester groups. J. Chem. Soc. (1999) 2983-2996.
76. OISHI S, TAMAMURA H, YAMASHITA M et al.: Stereoselective synthesis of a set of two functionalized (E)-alkene dipeptide isosteres of L-amino acid-L-Glu and L-amino acid-D-Glu. J. Chem. Soc., Perkin Trans. 1(2001) 2445-2451.
77. TAMAMURA H, HIRAMATSU K, UEDA S et al.: Stereoselective synthesis of [L-Arg, L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogs of the CXCR4 antagonist FC131. J. Med. Chem. (2005) 48:380-391.
78. TAMAMURA H, ARAKI T, UEDA S et al.: Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide-scaffolds. J. Med. Chem. (2005) 48:3280-3289.
79. MASTROLORENZO A, SCOZZAFAVA A, SUPURAN CT: Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. Expert Opin. Ther. Pat. (2001) 11:1245-1252.
80. SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. J. Enz. Inhib. Med. Chem. (2002) 17:69-76.
81. SCHOLS D, STRUYF S, VAN DAMME J, ESTE JA, HENSON G, DE CLERCQ E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. (1997) 186:1383-1388.
82. DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. (1997) 186:1395-1400.
83. DE CLERCQ E: New anti-HIV agents and targets. Med. Res. Rev. (2002) 22:531-565.
84. SEIBERT C, SAKMAR TP. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr. Pharm. Design 2004) 10:2041-2062.
85. VERMEIRE K, HATSE S, PRINCEN K et al.: Virus resistance to the CXCR4 inhibitor AMD070 develops slowly and does not induce a co-receptor switch. Antiviral Res. (2004) 62: A42-A43.
86. DAOUDI J-M, GREINER J, AUBERTIN A-M, VIERLING P: New bicyclam-GalCer analogue conjugates: synthesis and in vitro anti-HIV activity. Bioorg. Med. Chem. Lett. (2004) 14:495-498.
87. ICHIYAMA K, YOKOYAMA-KUMAKURA S, TANAKA Y et al.: A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA. (2003) 100:4185-4190.
88. CABRERA C, GUTIERREZ A, BARRETINA J et al.: Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Res. (2002) 53:1-8.
89. CABRERA C, GUTIERREZ A, BLANCO J et al.: Anti-human immunodeficiency virus activity of novel aminoglycoside-arginine conjugates at early stages of infection. AIDS Res. Hum. Retroviruses (2000) 16:627-634.
90. DAELEMANS D, SCHOLS D, WITVROUW M et al.: A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmacol. (2000) 57:116-124.
91. HOWARD OMZ, OPPENHEIM JJ, HOLLINGSHEAD MG et al.: Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application. J. Med. Chem. (1998) 41:2184-2193.
92. LIU D-Y, YE J-T, YANG W-H, YAN J, ZENG C-H, ZENG S: Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry. Biomed. Environ. Sci. (2004) 17:153-164.